Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study-Reference-Cited by-同舟云学术

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Published:2014-05-08 Issue:19 Volume:123 Page:2944-2952
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Flinn Ian W.¹,van der Jagt Richard²,Kahl Brad S.³,Wood Peter⁴,Hawkins Tim E.⁵,MacDonald David⁶,Hertzberg Mark⁷,Kwan Yiu-Lam⁸,Simpson David⁹,Craig Michael¹⁰,Kolibaba Kathryn¹¹¹²,Issa Samar¹³,Clementi Regina¹⁴,Hallman Doreen M.¹⁴,Munteanu Mihaela¹⁴,Chen Ling¹⁴,Burke John M.¹¹¹⁵

Affiliation:

1. Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;

2. Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada;

3. University of Wisconsin Carbone Cancer Center, Madison, WI;

4. Princess Alexandra Hospital, Brisbane, QLD, Australia;

5. Auckland Hospital, Auckland, New Zealand;

6. Dalhousie University, Halifax, NS, Canada;

7. Westmead Hospital, Westmead, NSW, Australia;

8. Concord Repatriation General Hospital, Concord, NSW, Australia;

9. North Shore Hospital, Takapuna, New Zealand;

10. West Virginia University, Morgantown, WV;

11. McKesson Specialty Health/US Oncology Research, The Woodlands, TX;

12. Compass Oncology, Vancouver, WA;

13. Middlemore Hospital, Auckland, New Zealand;

14. Teva Branded Pharmaceutical Products R&D, Inc., Frazer, PA; and

15. Rocky Mountain Cancer Centers, Aurora, CO

Abstract

Key Points The complete response rate for first-line bendamustine/rituximab was statistically noninferior to R-CHOP or R-CVP in indolent NHL or MCL. The safety profile of bendamustine/rituximab is distinct from that of R-CHOP/R-CVP.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/19/2944/1376284/2944.pdf

Reference17 articles.

1. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.;Hiddemann;Blood,2005

2. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.;Marcus;Blood,2005

3. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.;Knauf;J Clin Oncol,2009

4. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.;Kahl;Cancer,2010

5. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma.;Robinson;J Clin Oncol,2008

Cited by 520 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal number of cycles of bendamustine as initial chemoimmunotherapy for older patients with follicular lymphoma;Blood Neoplasia;2024-09

2. Lymphocyte recovery after bendamustine therapy in patients with mantle cell lymphoma. Results of a retrospective analysis and prognostic impact in the CAR-T era;Annals of Hematology;2024-08-30

3. Delphi consensus recommendations on treatment for advanced-stage marginal zone lymphoma in South Korea;Annals of Hematology;2024-08-06

4. Efficacy and Safety of Bendamustine-Rituximab as Frontline Therapy for Indolent Non-Hodgkin Lymphoma: A Real-World, Single-Center, Retrospective Study;Cureus;2024-08-04

5. Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance;Internal Medicine Journal;2024-08